High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma

INCLUSION CRITERIA

   - Stage II to III multiple myeloma, or progression after initial treatment of Stage I
   disease; early or relapsed

   - Age 18 to 75 years.

   - Pathology reviewed and the diagnosis confirmed at Stanford University Medical Center.

   - Patients with amyloidosis may be eligible for this trial, with approval by the
   Principle Investigator.

   - Patients must have a Karnofsky performance status > 70%.

   - Aspartate aminotransferase (AST) must be < 2 x upper limit of normal (ULN)

   - Alanine aminotransferase (ALT) must be < 2 x ULN

   - Total bilirubin < 2 mg/dL.

   - Serum creatinine < 2.0 or 24-hour creatinine clearance ≥ 60 mL/min.

   - Patients must be HIV-negative.

   - Patients must provide signed, informed consent.

EXCLUSION CRITERIA

   - Severe psychological or medical illness

   - Prior autologous hematopoietic cell transplantation

   - Pregnant

   - Lactating women

   - Smoldering multiple myeloma,

   - Monoclonal gammopathy of unknown significance or primary amyloidosis will be excluded
   from this study